Sigyn Therapeutics shareholder letter details expanded pipeline, S-1 financing, first-in-human study plans

Sigyn Therapeutics, Inc.

Company reveals four therapeutic platforms: Sigyn Therapy, ImmunePrep, ChemoPrep, and ChemoPure, with pending patent for chemotherapy delivery system.
S-1 registration statement filed with SEC to support underwritten financing; proceeds to advance programs and potentially qualify for Nasdaq listing.
First-in-human study of Sigyn Therapy targets ESRD patients with endotoxemia; 12-15 patient IDE drafted for FDA submission.
Clinical sites and principal investigators in place for Sigyn Therapy; treatment to be combined with dialysis.
Pipeline expansion includes devices to enhance performance of immunotherapeutic antibodies and chemotherapy delivery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.